R2 in the Treatment of Follicular Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Follicular Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 16 years and 75 years
- Gender
- Both males and females
Description
Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma
Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma
Tracking Information
- NCT #
- NCT03715309
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon